Section
Pipeline
Late-stage drugs with significant commercial implications
PipelineFierceBiotech ↗
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person sy…
Pipeline
Roche’s Enspryng cut MOGAD relapse risk by 68%, a pivotal step toward the first FDA-approved therapy for the d…
PipelineBioPharma Dive ↗
A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private c…
PipelineSTAT News ↗
Flu shot no longer mandated for U.S. troops, "healthy" snacks, and other news from Morning Rounds…
PipelineFierceBiotech ↗
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, R…
PipelineFiercePharma ↗
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blo…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.